Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Control Mechanism Behind Autoimmune Diseases Discovered

May 5, 2010 7:05 am | News | Comments

Researchers at the Swedish medical university Karolinska Institutet have discovered a new control mechanism in our immune system.

TOPICS:

Trauma-Induced Genetic Changes May Lead To PTSD

May 5, 2010 7:01 am | News | Comments

A study at Columbia University's Mailman School of Public Health suggests that traumatic experiences "biologically embed" themselves in select genes, altering their functions and leading to the development of post-traumatic stress disorder.

TOPICS:

FDA Approves Vyvanse PI Change

May 5, 2010 6:46 am | News | Comments

Shire plc announced that the US Food and Drug Administration approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment, Vyvanse.

TOPICS:
Advertisement

InterMune Shares Plummet on Esbriet News

May 5, 2010 6:38 am | by Marley Seaman | News | Comments

Shares of InterMune crashed in premarket trading Wednesday after regulators asked the company to perform additional tests on its lung disease drug Esbriet, potentially delaying its approval by years.

TOPICS:

FDA Looking for Ways to Stop DXM Abuse

May 5, 2010 6:32 am | News | Comments

The Food and Drug Administration has scheduled a meeting to discuss ways to curb abuse of a key ingredient found in Robitussin and other cough suppressing medicines.

TOPICS:

New Option for Severe Asthma Sufferers

May 5, 2010 6:27 am | by Lauran Neergaard | News | Comments

People with severe asthma are getting a radically different treatment option: A way to snake a wire inside their lungs and melt off some of the tissue that squeezes their airways shut.

TOPICS:

Merck Q1 Profits Drop Due to Acquisition

May 5, 2010 6:24 am | News | Comments

Drugmaker Merck & Co. said double-digit sales growth for a half-dozen of its top medicines fueled a 7 percent jump in first-quarter sales. But charges for its November deal to buy Schering-Plough Corp. pulled profit down sharply.

TOPICS:

FDA Orders Baxter to Destroy Colleague Pumps

May 5, 2010 6:19 am | News | Comments

Shares of Baxter International Inc. fell to three-year lows after the medical device maker said the Food and Drug Administration wants it to recall and destroy its Colleague infusion pumps.

TOPICS:
Advertisement

Pfizer Profits Down On Wyeth Charges

May 5, 2010 6:13 am | by Linda A. Johnson | News | Comments

Drugmaker Pfizer Inc. reported a huge jump in its first-quarter revenue, thanks to its giant acquisition of Wyeth last October, but charges from the deal weighed down net income for the world's biggest drugmaker.

TOPICS:

FDA Found Bacteria in Recalled Tylenol

May 5, 2010 6:09 am | by Matthew Perrone | News | Comments

Ingredients used by Johnson & Johnson in some of the 40 varieties of children's cold medicines recalled last week were contaminated with bacteria, according to a report by the Food and Drug Administration.

TOPICS:

Novartis Settling Whistleblower Suit for $72.5M

May 5, 2010 6:05 am | News | Comments

Swiss pharmaceutical company Novartis AG is paying $72.5 million to settle a whistleblower lawsuit accusing it of improperly billing government programs for unapproved uses of a cystic fibrosis drug.

TOPICS:

Spectrophotometer

May 4, 2010 7:44 am | Product Releases | Comments

Thermo Fisher Scientific Inc. announced that its NanoDrop 2000c UV-Vis Spectrophotometer significantly improves the protein quantitation process.

TOPICS:

Coated Plates

May 4, 2010 7:36 am | Product Releases | Comments

G-Biosciences offers a large selection of coated 96-well plates, known as Well-Coated plates.

TOPICS:

Warnex And Epigenomics Sign Septin9 Agreement

May 4, 2010 7:31 am | News | Comments

Warnex Medical Laboratories, a division of Warnex Inc., and Epigenomics AG, have entered into a non-exclusive licensing agreement for Epigenomics' colorectal cancer biomarker Septin9.

TOPICS:

BMS Board Authorizes $3B Stock Buyback

May 4, 2010 7:23 am | News | Comments

Bristol-Myers Squibb Company announced its Board of Directors has authorized the repurchase of up to $3 billion of its common stock.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading